Grass and rye pollen allergen-specific Immunoglobulin E (sIgE)

Grass and rye pollen allergen-specific IgE antibodies are a specialized subset of Immunoglobulin E (IgE) that recognize and bind to proteins found in the pollen of various grass species, such as Timothy grass (Phleum pratense) and Perennial rye grass (Lolium perenne) [1.1.2, 1.2.4]. These antibodies are the primary drivers of Type I hypersensitivity reactions, which manifest as seasonal allergic rhinitis (hay fever) and allergic asthma [1.2.1, 1.3.4]. When these specific IgE antibodies, bound to high-affinity receptors (FcεRI) on mast cells and basophils, encounter their cognate allergens, they trigger the rapid release of inflammatory mediators like histamine and leukotrienes [1.2.1]. In clinical practice, these antibodies are both a diagnostic marker for sensitization and a key therapeutic target [1.2.3, 1.3.4]. Treatments include anti-IgE monoclonal antibodies like Omalizumab, which sequester IgE to prevent receptor binding, and allergen-specific immunotherapy (AIT), which uses allergen extracts to desensitize the immune system and induce protective IgG4 blocking antibodies [1.2.1, 1.3.3]. Monitoring the levels and activity of these specific IgE antibodies is crucial for patient selection and for evaluating the success of therapeutic interventions [1.2.3, 1.3.1].

Other names

Grass pollen-specific IgERye pollen-specific IgEAllergen-specific IgESpecific Immunoglobulin EsIgE

Anti-IgE monoclonal antibodies like Omalizumab bind to the Fc region of IgE, preventing its interaction with the high-affinity receptor FcεRI on mast cells and basophils, thereby inhibiting the release of allergic mediators. Allergen-specific immunotherapy (AIT) involves the administration of specific allergens to induce immune tolerance, characterized by a shift from Th2 to Th1 responses, the induction of regulatory T cells, and the production of IgG4 'blocking antibodies' that compete with IgE for allergen binding.